Share This Article:

Use of the LigaSureTM in Cervicofacial Venous Malformation Excision

Abstract Full-Text HTML Download Download as PDF (Size:178KB) PP. 104-107
DOI: 10.4236/mps.2013.33021    3,261 Downloads   4,629 Views  

ABSTRACT

Complete surgical excision of venous malformations (VMs) is frequently complicated by massive bleeding and nerve damage, particularly in the cervicofacial area. This report describes a novel technique for the resection of cervicofacial VMs using the LigaSureTM (Valleylab, Tyco International Healthcare, Boulder, CO) vessel sealing system. We report three cases of VM excision using this vessel sealing system, and recorded intraoperative and postoperative blood loss, operative time, and postoperative complications. In all cases employing the LigasureTM, perioperative blood loss was less than 600 ml, no patients developed postoperative hematomas or other bleeding complications, and no patients developed a facial palsy even if the VM was located close to the facial nerve. LigaSureTM provides excellent hemostasis with few complications when used for cervicofacial VMs.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

E. Konno, E. Ochi, H. Ogata and K. Kishi, "Use of the LigaSureTM in Cervicofacial Venous Malformation Excision," Modern Plastic Surgery, Vol. 3 No. 3, 2013, pp. 104-107. doi: 10.4236/mps.2013.33021.

References

[1] L. M. Buckmiller, G. T. Richter, M. Waner and J. Y. Suen, “Use of Recombinant Factor VIIa during Excision of Vascular Anomalies,” Laryngoscope, Vol. 117, No. 4, 2007, pp. 604-609. doi:10.1097/MLG.0b013e318030450e
[2] C. A. James, L. E. Braswell, L. B. Wright, et al., “Preoperative Sclerotherapy of Facial Venous Malformations: Impact on Surgical Parameters and Long-Term FollowUp,” Journal of Vascular and Interventional Radiology, Vol. 22, No. 7, 2011, pp. 953-960. doi:10.1016/j.jvir.2011.03.004
[3] L. Su, X. Fan, L. Zheng and J. Zheng, “Absolute Ethanol Sclerotherapy for Venous Malformations in the Face and Neck,” Journal of Oral and Maxillofacial Surgery, Vol. 68, No. 7, 2010, pp. 1622-1627. doi:10.1016/j.joms.2009.07.094
[4] S. Hoque and B. K. Das, “Treatment of Venous Malformations with Ethanolamine Oleate: A Descriptive Study of 83 Cases,” Pediatric Surgery International, Vol. 27, No. 5, 2011, pp. 527-531. doi:10.1007/s00383-010-2824-x
[5] B. E. Cil, I. Vargel, S. Geyik, B. Peynircioglu and T. Cavusoglu, “Venous Vascular Malformations of the Craniofacial Region: Pre-Operative Embolisation with Direct Percutaneous Puncture and N-Butyl Cyanoacrylate,” British Journal of Radiology, Vol. 81, No. 972, 2008, pp. 935-939. doi:10.1259/bjr/66893325
[6] K. Scherer and M. Waner, “Nd:YAG Lasers (1,064 nm) in the Treatment of Venous Malformations of the Face and Neck: Challenges and Benefits,” Lasers in Medical Science, Vol. 22, No. 2, 2007, pp. 119-126. doi:10.1007/s10103-007-0443-0
[7] S. L. Peterson, P. L. Stranahan, D. Schmaltz, C. Mihaichuk and N. Cosgriff, “Comparison of Healing Process Following Ligation with Sutures and Bipolar Vessel Sealing,” Surgical Technology International, Vol. 10, 2002, pp. 55-60.
[8] G. R. Lamberton, R. S. Hsi, D. H. Jin, T. U. Lindler, F. C. Jellison and D. D. Baldwin, “Prospective Comparison of Four Laparoscopic Vessel Ligation Devices,” Journal of Endourology, Vol. 22, No. 10, 2008, pp. 2307-2312. doi:10.1089/end.2008.9715
[9] F. J. Kim, M. F. Chammas Jr., E. Gewehr, et al., “Temperature Safety Profile of Laparoscopic Devices: Harmonic ACE (ACE), Ligasure V (LV), and Plasma Trisector (PT),” Surgical Endoscopy, Vol. 22, No. 6, 2008, pp. 1464-1469. doi:10.1007/s00464-007-9650-9
[10] E. Konno and K. Kishi, “Use of the LigaSure (TM) Vessel Sealing System in Neurofibroma Excision to Control Postoperative Bleeding,” Journal of Plastic, Reconstructive & Aesthetic Surgery, Vol. 65, No. 6, 2012, pp. 814-817.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.